Hyperkalemia

Hyperkalemia- Etiology



- Hypoaldosteronism
- Volume depletion

Pseudohyperkalemia

Hemolysis via small needle (traumatic Venipuncture)

- The most common cause is lysis of red cells in a phlebotomy specimen.
- Delayed analysis.
- Excessive tourniquet.
- Severe Thrombocytosis. Potassium released from platelets
- Severe Leukocytosis.

Pseudohyperkalemia can be excluded by repeating the sample as atraumatically as possible.

Redistribution (ICF to ECF)

Acidosis

- Hyperkalemic periodic paralysis (AD disease)
 Insulin deficiency (DKA).
- Tissue damage (Tumor lysis ,Burn injury ,Crush injury, Surgery , Massive Hemolysis)

Medications:

Beta Blockers Digitalis intoxication (Digoxin Toxicity)

Decreased renal excretion

Renal Insufficiency or Renal Failure. Renal Tubular Acidosis (Type 4) =(hyporeninimic hypoaldostronism) Adrenal Insufficiency (Addison's).

Medication.

- Heparin .
- Cyclosporine
- ACE Inhibitor
- Potassium sparing Diuretics
- NSAIDS

The initial diagnostic approach begins with the clinical history, review of medications, and physical examination.

Symptoms and signs include muscular weakness or flaccid paralysis, paralytic ileus, and characteristic ECG changes.

Symptoms and Signs

- 3 types of muscle fibres (skletal, smooth ,cardiac).
- May be asymptomatic
- Irregular heartbeat
- Fatigue
- Tingling, numbness, or paraethesia
- Weakness
- Paralysis (in some population with AD hyperkalemic periodic paralysis)
- Difficult breathing

ECG

Mild hyperkalemia 5.5-6 mmol/L peaked T
 Moderate 6-8 mmol/L, peaked T + <u>absent P wave</u>
 Severe > 8 mmol/L, peaked T <u>absent P wave</u>, wide QRS, Vent arrhythmia, VF, asystole



TARGET OF TREATMENT

- Minimize membrane depolarization(Ca gluconate)
- Shifting k into cells (glucose- insulin , bicarb, B2 agonist)
- Promote k loss (diuretics) but be sure of functioning kidney
- Correction of acidosis (Na bicarb.)
- D/C exogenous k sources , antikaliuretic drugs (stop aldacton ,NSAID & ACE I)

Serious hyperkalemia = Plasma K> 7.5 mmol/L Profound weakness Absent P wave, wide QRS, vent arrhythmia. Intravenous calcium is administered to stabilize the myocardium; it lowers the threshold potential, thus counteracting the toxic effect of high potassium. Calcium does not have any effect on the serum potassium level. Improvement in the ECG changes should be visible within two to three minutes of administration of calcium

Medications Used in Acute Treatment of **Hyperkalemia**

Calcium gluconate

Dosage 10 to 20 mL of 10 percent solution IV over two to three minutes

Onset Immediate

30 minutes

Two to

effect

Length of

Protects myocardium from toxic effects of K; no effect on serum potassium level

Mechanism of action

Cautions

Can worsen digoxin toxicity

Insulin

Regular insulin 10 units IV with 50 mL of 50 percent glucose

15 to 30 minut es

Shifts potassium out of six hours the vascular space and into the cells; no effect on total body

potassium

Consider 5 percent dextrose solution infusion at 100 mL per hour to prevent hypoglycemia with repeated doses. Glucose unnecessary if blood sugar elevated above 250 mg per dL

Albuterol (Ventolin)	10 to 20 mg by nebulizer over 10 minutes (use concentrated form, 5 mg per mL)	15 to 30 minutes	Two to three hours	Shifts potassium into the cells, additive to the effect of insulin; no effect on total body potassium	May cause a brief initial rise in serum potassium
Furosemide (Lasix)	20 to 40 mg IV, give with saline if volume depletion is a concern	15 minutes to one hour	Four hours	Increases renal excretion of potassium	Only effective if adequate renal response to loop diuretic
Sodium polystyrene Cation exchange resin (sorpstret powder) (Q) in resistant hyperkalem ja	Oral: 50 g in 30 mL of sorbitol solution Rectal: 50 g in a retention enema	One to two hours (rectal route is faster) 1gm binds 1mmol k	Four to six hours	Removes potassium from the gut in exchange for sodium	Sorbitol may be associat ed with bowel necrosis. May lead to sodium retention
hemodiatysis	The most rapid and effective	PD is 15% as effective as HD			

Hyporeninemic hypoaldosteronism(RTA type 4) should be considered in patients with diabetes and hyperkalemia, a trial of oral fludrocortisone (asetonin H)^R (aldosteron like miniralocorticoides) to establish this diagnosis;

potassium levels will return to **normal** in a day or two after initiation of fludrocortisone.